The present disclosure includes, among other things, lipids, compositions, and methods useful for delivering a polynucleotide or oligonucleotide, e.g., viral genome.

The present disclosure includes, among other things, lipids, compositions, and methods useful for delivering a polynucleotide or oligonucleotide, e.g., viral genome.

A composition is prepared from a platinum-based antitumor compound and a novel compound, and the novel compound is sodium(S)-2-(dithiocarboxylate ((2S, 3R, 4R, 5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-4-(methylthio)butyrate. The novel compound in the composition could effectively chelate the platinum-based antitumor compound and reduce the various adverse effects exhibited by the platinum-based compound. The dosage of the platinum-based antitumor compound can thus be increased, and the antitumor effect can be optimized. The novel compound itself is low-toxic and it has low chelating activities with essential metals in the human body; it would not impose significant adverse effects on the human body at given doses. The composition and its application as an antitumor drug overcome some technical drawbacks of platinum-based antitumor drugs, namely severe adverse effects and the development of drug resistance during administration.

A composition is prepared from a platinum-based antitumor compound and a novel compound, and the novel compound is sodium(S)-2-(dithiocarboxylate ((2S, 3R, 4R, 5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-4-(methylthio)butyrate. The novel compound in the composition could effectively chelate the platinum-based antitumor compound and reduce the various adverse effects exhibited by the platinum-based compound. The dosage of the platinum-based antitumor compound can thus be increased, and the antitumor effect can be optimized. The novel compound itself is low-toxic and it has low chelating activities with essential metals in the human body; it would not impose significant adverse effects on the human body at given doses. The composition and its application as an antitumor drug overcome some technical drawbacks of platinum-based antitumor drugs, namely severe adverse effects and the development of drug resistance during administration.

What is described is a compound having the formula

##STR00001##

wherein R.sub.1 is branched alkyl of the structure (CH.sub.3(CH.sub.2).sub.m).sub.2CH, wherein m is 2 or 3; R.sub.2 is a linear alkyl of 1, 2, 3, 4, 5, 6, 7, 8, or 9 carbons, a branched alkyl of 3, 4, 5, 6, 7, 8, or 9 carbons, or an alkenyl or alkynyl of 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 carbons; R.sub.3 is (CH.sub.2).sub.p, wherein p is 2, 3, 4, 5 or 6; R.sub.4 and R.sub.5 are the same or different, each a hydrogen, or a linear or branched alkyl of 1, 2, 3, 4, 5 or 6 carbons; L.sub.1 and L.sub.2 are the same or different, of the structure (CH.sub.2).sub.n, wherein n is 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18; L.sub.3 is a bond; X.sub.1 is COO whereby L.sub.1COOR.sub.2 is formed; X.sub.2 is S or O; and X.sub.3 is COO whereby L.sub.1COOR.sub.1 is formed; and
wherein m+n+p is 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27;
or a pharmaceutically acceptable salt thereof.

What is described is a compound of formula I

##STR00001## wherein X is an alkylene or an alkenylene; Y is a monocyclic, bicyclic, or tricyclic arene or heteroarene; Z is S or O; L is a linear or branched alkylene of 1 to 6 carbons; R.sub.1 is a branched alkyl or alkenyl of 1 to 25 carbons; R.sub.2 is a alkyl or alkenyl of 1 to 20 carbons; R.sub.3 and R.sub.4 are independently a linear or branched alkyl of 1 to 6 carbons; n is 0 to 6; and m, p, q, and r are independently 1-18; or a pharmaceutically acceptable salt thereof.

What is described is a compound of formula I

##STR00001## wherein X is an alkylene or an alkenylene; Y is a monocyclic, bicyclic, or tricyclic arene or heteroarene; Z is S or O; L is a linear or branched alkylene of 1 to 6 carbons; R.sub.1 is a branched alkyl or alkenyl of 1 to 25 carbons; R.sub.2 is a alkyl or alkenyl of 1 to 20 carbons; R.sub.3 and R.sub.4 are independently a linear or branched alkyl of 1 to 6 carbons; n is 0 to 6; and m, p, q, and r are independently 1-18; or a pharmaceutically acceptable salt thereof.

What is described is a compound of formula I ##STR00001##
wherein R.sub.1 is a linear alkyl, alkenyl, or alkynyl of 2 to 12 carbons, or a branched alkyl with 12 to 20 carbons, R.sub.2 is a branched alkyl with 12 to 20 carbons, L.sub.1 and L.sub.2 are independently a linear alkylene with 1-18 carbons or alkenylene with 2-18 carbons, X is S or O, L.sub.3 is a bond or an alkylene with 1 to 6 carbons, R.sub.3 is an alkylene with 1 to 6 carbons, and R.sub.4 and R.sub.5 are the same or different, each a linear or branched alkyl with 1 to 6 carbons.

What is described is a compound of formula I ##STR00001##
wherein R.sub.1 is a linear alkyl, alkenyl, or alkynyl of 2 to 12 carbons, or a branched alkyl with 12 to 20 carbons, R.sub.2 is a branched alkyl with 12 to 20 carbons, L.sub.1 and L.sub.2 are independently a linear alkylene with 1-18 carbons or alkenylene with 2-18 carbons, X is S or O, L.sub.3 is a bond or an alkylene with 1 to 6 carbons, R.sub.3 is an alkylene with 1 to 6 carbons, and R.sub.4 and R.sub.5 are the same or different, each a linear or branched alkyl with 1 to 6 carbons.

The present invention relates to carbamoyl phenylalaninol analogs and methods of using the same to treat disorders.